Kornimate/medical-research-clean huggingface dataset:
effects of mills manipulation and nirschel exercises in patients with lateral epicondylitis

Conditions: Lateral Epicondylitis

Summary: to find effects of mills manipulation versus nirschl exercises on pain ,strength and function in patients with lateral epicondylitis.

lateral epicondylitis is also known as tennis elbow, an overuse injury that is characterized by pain and tenderness over the lateral epicondyle. the exact etiology has not been well identified, however its commonly associated with repetitive micro trauma from excessive gripping, wrist extension radial deviation or forearm supination. extensor carpi radialis brevis is the most affected muscle. the aim of this study is to access the effects of mills manipulation versus nirschl exercises on pain, strength, and function in patients with lateral epicondylitis. this study will be a randomized clinical trial and will be conducted at pakistan society for rehabilitation of disabled and mayo hospital in lahore. patients of aged 20-40 years having insidious onset of lateral elbow pain with positive cozens test, mills test and maudsley test will be taken. patients with radial nerve entrapment, cervical radiculopathy and those receiving injections of corticosteroids in last 4 weeks are excluded. the study will include 32 patients randomly divided into two groups a and group b. the study will be completed within the time duration of 10 months after approval of synopsis. group a will receive mills manipulation while group b will receive nirschl exercises. myofascial release therapy will be given to both groups as baseline. both groups will receive 3 sessions per week for 4 weeks (12 sessions), data will be taken by using numeric pain rating scale for pain, hand dynamometer for grip strength and patient rated tennis elbow evaluation for evaluation of function, at the start of treatment and the end of treatment session. data will be analysed on spss-25. key words: lateral epicondylitis, mills manipulation, nirschl exercises, patient rated tennis elbow evaluation

Eligibility criteria:
inclusion criteria: * pain on lateral epicondyle of humerus when palpated, in the age group of 40-60 years * both male and female are included * unilateral symptomatic lateral epicondylitis * tenderness over palpation of extensor carpi radialis brevis muscle muscle (ecrb) * patients with positive cozens test (resisted wrist extension and radial deviation is painful) ,mills test (passive elbow extension \& wrist flexion is painful) and maudsley test(resisted middle finger extension is painful) * patients having symptoms of lateral epicondylitis for \> 3 months exclusion criteria: * radial nerve entrapment * cervical radiculopathy * corticosteroid injection within 4 weeks * had received any conservative treatment for lateral epicondylitis in last 4 weeks before entering the study * post-surgery patients of lateral epicondylitis * radiological findings of extensor tendon calcification

Keywords: lateral epicondylitis ,mills manipulation,nirschl exercises
vitamin d, hashimato's thyroiditis and thyroid functions

Conditions: Vitamin D; Thyroid Autoimmune Disease

Summary: the goal of this retrospective observational study is to determine whether vitamin d levels differ in patients with hashimoto's thyroiditis (ht) compared to those without hashimoto's thyroiditis. the main research questions are: are vitamin d levels lower in ht patients compared to non-ht patients? do vitamin d levels vary between ht and non-ht patients based on thyroid function status? the study was conducted by retrospectively reviewing the medical records of patients who visited the hospital outpatient clinic.


Eligibility criteria:
inclusion criteria: patients with the following biochemical parameters: * vitamin d (25(oh)d) levels * thyroid-stimulating hormone (tsh) levels * free triiodothyronine (ft3) levels * free thyroxine (ft4) levels * anti-thyroid peroxidase (anti-tpo) levels * anti-thyroglobulin (anti-tg) levels exclusion criteria: -

Keywords: vitamin d thyroid autoimmunity hashimato's thyroiditis thyroid functions
acceptance and commitment therapy in patients with advanced lung cancer

Conditions: Lung Cancer; Advanced Cancer

Summary: lung cancer is a malignant tumor that has transformed from a single cancer disease into one of the most striking global health problems. lung cancer has an insidious onset, and most patients are first diagnosed with the middle and advanced stage. cancer related fatigue is the most common and distressing symptom reported by lung cancer patients. for cancer patients, fatigue has lasting impact on physical, psychological and social functions, interferes with activities and participating in life events, thereby worsening the health-related quality of life. acceptance and commitment therapy (act) is the third-wave cognitive behavioral therapy to improve functioning and health-related quality of life by increasing psychological flexibility. the study aims to examine the effectiveness of act on fatigue interference and health-related quality of life in patients with advanced lung cancer.

a two-arm, assessor-blind randomized controlled trial will be conducted to investigate the effects of act on advanced lung cancer patients compared to usual care. participants in the same ward will be randomized at a 1:1 ratio to the intervention group or control group. block randomization will be conducted by an independent research assistant using randomly varying block size of 4, 6 to avoid selection bias. the study aims to examine the effectiveness of act on fatigue interference and health-related quality of life in patients with advanced lung cancer. the specific objectives are: 1) to investigate the effects of act on primary outcomes: fatigue interference and health-related quality of life compared to control group at post-intervention and three months follow-up. 2) to investigate the effects of act on the secondary outcomes: cancer-related fatigue, depressive symptoms, anxiety, distress and exercise capacity and process outcomes including psychological flexibility, act related variables (acceptance and cognitive defusion) at post-intervention and three months follow-up.

Eligibility criteria:
inclusion criteria: 1. aged 18 or over; 2. diagnosed with stage iii or stage iv lung cancer by pathological section or cytology; 3. experienced unexplained fatigue syndrome: the score of 3 or more on the fatigue symptom inventory (fsi); and 4. able to provide informed consent and effectively collect data. exclusion criteria: 1. diagnosed with cognitive dysfunction or other mental illnesses that may interfere with their completion of treatment; 2. who are with a life expectancy \<3 months, or whose physical conditions are considered ineligible for the present study based on the physician's judgment; and 3. who are receiving or have just completed other lung cancer-related intervention programs within the last six months

Keywords: lung cancer palliative care acceptance and commitment therapy fatigue health-related quality of life
phase ii study of abi-007 for gastric cancer

Conditions: Gastric Cancer

Summary: the purpose of this study is to evaluate the efficacy and safety of tri-weekly abi-007 for recurrence or unresectable gastric cancer patients who have received one prior regimen containing fluoropyrimidine and developed disease progression or recurrence.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed gastric adenocarcinoma * received one prior regimen containing fluoropyrimidine analogs and developed disease progression or recurrence * age: 20 - 74 * at least one measurable lesion by recist criteria exclusion criteria: * history of taxans use * patients with another active malignancy * pre-existing peripheral neuropathy of grade 2, 3, or 4 (per ctcae) * chronic treatment with steroids
efficacy of an oral stimulation protocol in preterm infants to shorten the period between enteral and oral nutrition

Conditions: Infant, Premature, Diseases

Summary: oral feeding in the neonatal period requires an accurate coordination between suction, swallowing and breathing. in premature new-borns and, depending on their gestational age, the coordinated work of those processes becomes jeopardised, being necessary to begin with an artificial enteral feeding. this situation results in lengthen their stay at the hospital until they are able to respond in a reliable way to their nutritional requirements orally, maintaining an adequate daily weight gain and without endangering their cardiorespiratory system. this project is an experimental, prospective, blinded, randomized study, aimed to determine whether the application of a manual oral stimulation protocol in premature infants, hospitalized in a neonatal unit, reduces the transition time from enteral feeding to oral full feeding, while improves quality of feeding and shortens hospitalization time.


Eligibility criteria:
inclusion criteria: * babies between 25 + 0 to 30 + 6 weeks of gestation according to the last menstruation, with adequate weight and size for their gestational age, who are receiving orogastric tube feeding, presenting clinical hemodynamic and cardiorespiratory stability and without any associated pathology. exclusion criteria: * babies with congenital anomalies that affect feeding (chromosomopathies, craniofacial anomalies, severe esophageal or tracheal atresia, or any other that affect feeding), * babies with abnormalities that alter digestive function such as "necrotizing enterocolitis". * babies with other abnormalities that alter hemodynamic or cardiorespiratory stability, that present severe sepsis or positive meningitis culture, that suffer from chronic medical complications such as severe bronchopulmonary dysplasia, grade iii or iv intraparaventricular hemorrhage, periventricular leukomalacia, etc., * inability to to assign an exact gestational age.

Keywords: oral feeding oral stimulation physiotherapy intervention
pneumatic compression vs blood flow restriction for muscle recovery

Conditions: Delayed Onset Muscle Soreness

Summary: both bfr and intermittent pneumatic compression are purported to decrease symptoms associated with exercise induced muscle damage (eimd) that cause delayed onset muscle soreness (doms). blood flow restriction relies on applying pressurized cuffs to the most proximal portion of the limb. another form of recovery often relied upon is pneumatic compression. the mechanism by which pneumatic compression works is similar to that of a massage, whereby the device progressively increases the pressure on a portion of the limb before releasing and moving further up the limb.the purpose of this study is determine whether bfr or pneumatic compression can be used to decreased doms which may indicate enhanced recovery.


Eligibility criteria:
inclusion criteria: * 18-30 years of age * recreationally active population * women should be on a form of hormonal contraception. * no current musculoskeletal injuries or pathologies * must answer "yes" to all par-q questions. exclusion criteria: * individuals that routinely train trail running * discomfort when running * deep vein thrombosis * blood clots * cancerous lesions * sensory or mental impairment * unstable fractures * acute pulmonary edema * acute thrombophlebitis * acute congestive cardiac failure * acute infections * episodes of pulmonary embolism * wounds, lesions, infection, or tumors * bone fractures or dislocations * increased venous and lymphatic return * answers "no" to any of the par-q screening questions
a phase iii clinical study to evaluate the efficacy and safety of gzr18 injection in adult type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus (T2DM)

Summary: the main purpose of this study is to investigate the efficacy and safety of gzr18 injection in chinese subjects with type 2 diabetes mellitus and poor blood glucose control by metformin monotherapy or in combination with sodium-dependent glucose transporter 2 (sglt2) inhibitors or sulfonylureas


Eligibility criteria:
inclusion criteria: * t2dm is diagnosed for at least 12 weeks according to the diagnostic criteria of diabetes mellitus issued by the world health organization (who) in 1999 and the supplementary diagnostic criteria of who in 2011 (hba1c diagnosis is recommended). * antidiabetic drugs that meet any of the following within 8 weeks before screening: * a stable dose of metformin hydrochloride monotherapy at a dose of ≥ 1500 mg/day or the maximum tolerated dose ; * a stable dose of metformin (≥ 1500 mg/day or the maximum tolerated dose ) in combination with sglt2 inhibitors; * a stable dose of metformin (≥1500 mg/day or a maximum tolerated dose \< 1500 but ≥ 1000 mg/day) in combination with a stable daily dose of sulfonylureas. * hba1c ≥ 7.5% and ≤ 11% at screening (central laboratory). * bg \< 15 mmol/l at screening (central laboratory). exclusion criteria: * type 1 diabetes mellitus or special type of diabetes mellitus. * diabetic ketoacidosis, diabetic lactic acidosis or hyperosmolar state within 6 months before screening, or diabetic ketosis at screening/before randomization. * severe chronic complications of diabetes (such as proliferative retinopathy or maculopathy, diabetic painful neuropathy, intermittent claudication, or diabetic foot) at screening or before randomization. * history of acute or chronic pancreatitis and pancreatic injury before screening. * history or relevant family history of medullary thyroid cancer, multiple endocrine neoplasia (men) 2a or 2b before screening. * any laboratory test indicator meeting the following criteria at screening or before randomization: * calcitonin level ≥ 50 ng/l (pg/ml) at screening. * alt ≥ 3.0 × upper limit of normal (uln) or ast ≥ 3.0 × uln or total bilirubin ≥ 2.0 × uln. * estimated glomerular filtration rate (egfr) \< 60 ml/min/1.73 m2, calculated using ckd-epi equation (see appendix 3). * fasting triglyceride (tg) ≥ 5.7 mmol/l or 500 mg/dl. * blood amylase or lipase \> 1.5 × uln. * hemoglobin ≤ 100 g/l for women and ≤ 110 g/l for men.
identification of biomarkers in spinocerebellar ataxia 3

Conditions: Spinocerebellar Ataxia Type 3

Summary: the purpose of this study is to examine the differences in cerebral spinal fluid (csf) and blood of patients with spinocerebellar ataxias and healthy volunteers. the goal of this project is to identify new biomarkers that are useful for characterizing spinocerebellar ataxias and identify targets for treatment or prevention of this condition.

participants will undergo a sara exam, a lumbar puncture and a blood draw. a lumbar puncture is a procedure in which a small amount of the spinal fluid that surrounds the brain and spinal cord is removed by inserting a needle in the lower back. participants will be asked not to eat or drink anything (water is acceptable) for at least 6 hours before the lumbar puncture visit. for this procedure, participants will be positioned lying on their side and curled up in a ball, or sitting up and bent forward, whichever is easier. cushions will be used to enhance comfort. the lower back region will be cleaned and disinfected with an antiseptic iodine solution. the doctor will inject local anesthetic (lidocaine, 1%) into the skin of the lower back. this may produce a transient, mild burning sensation. a very small needle will be introduced into the skin and moved into fluid-filled space around the spinal nerves coming from the spinal cord. this may produce a pressure sensation. approximately 2 tablespoons approximately 30 ml) of fluid will be collected. the needle will be removed and a band-aid applied over the needle insertion site. participants will be asked to remain stationary, lying on flat for about ½ hour on a bed in the research clinic. participants will be given something to eat and drink before leaving. strenuous physical activity should be avoided for the next 24 hours. this includes lifting, bending, doing housework and gardening, or doing exercise such as jogging or bicycle riding. the sara (scale for the assessment and rating of ataxia) exam is a clinical scale that assesses a range of different impairments in cerebellar ataxia. the scale is made up of 8 items related to gait, stance, sitting, speech, fingerchase test, nose-finger test, fast alternating movements and heel-shin test, and takes approximately 15 minutes to complete. the study also involves a single collection of about 3.5 tablespoons (approximately 50 ml) of blood. this blood draw may take place during a regularly scheduled visit to the neurology clinic or at the research appointment.

Eligibility criteria:
inclusion criteria: •confirmed genetic testing of sca3 or healthy volunteers exclusion criteria: * people with: * unstable thyroid * unstable intestinal/stomach issues * unstable heart issues * unstable liver issues * unstable kidney issues * unstable lung issues * unstable hormone issues * unstable mental disorders at screening * a tumor or evidence of having a tumor * a chronic infection or any severe acute infection within 3 months prior to screening * people who: * take anti-coagulants and nsaids * have started any investigational medications in the last month * women who are pregnant or breast feeding
a phase 1 dose escalation study of intravenous vx-993 in healthy adults

Conditions: Pain

Summary: the purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (pk) of intravenously administered vx-993 at different doses in healthy participants.

this clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (that is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(a) of the public health service act and 42 cfr 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the public health service act or 42 cfr 11.24 and 11.44.).

Eligibility criteria:
key inclusion criteria: * body mass index (bmi) of 18.0 to 32.0 kilogram per meter square (kg/m\^2), inclusive * a total body weight of more than (\>) 50 kg * nonsmoker or ex-smoker for at least 3 months before first dose of the study drug key exclusion criteria: * history of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug. * any condition possibly affecting drug distribution, metabolism, or excretion other protocol defined inclusion/exclusion criteria may apply.
assessment of inspiratory muscles strength and endurance evolution on difficult to wean patients in intensive care unit

Conditions: Weaning From Mechanical Ventilation

Summary: ventilator-induced diaphragmatic dysfunction appears to contribute to slow weaning from mechanical ventilation. several trials of inspiratory muscle training to facilitate weaning in intensive care have been performed, with inconsistent results, utilizing different methods of imt in different populations. to perform the best imt program, we need to know the physio-pathology of the diaphragm in difficult to wean patients. this study proposes to discriminate the two main characteristics of the inspiratory muscles: strength and endurance. by analyzing the evolution of strength and endurance during all the weaning period, we want to know which characteristic has the more deficiency to adapt in a second time an effective program of imt.

the main objective of this study is to determinate which characteristic of inspiratory muscles between strength and endurance has more deficiency in difficult to wean patients. in a second time, the results of this study will help to choose the best imt program to assess his impact on the weaning time. we are going to conduct an interventional trial because of peak pressure measure, which is not measure in care practice. following 18h of invasive mechanical ventilation in a controlled mode, the failure of the first single breathe trial of 2 hours and the presence of sevrability criterias defined by the european consensus conference in 2007, 80 participants will be included in the medical intensive care unit of bordeaux's hospital. we'll perform measurements of the maximal inspiratory pressure and peak pressure from the inclusion to the extubation.

Eligibility criteria:
inclusion criteria: * patient ventilated more than 18h in a controlled mode; * first single breathe trial of 2 hours failure; * presence of sevrability criterias definied by the european consensus conference in 2007 as usually used: * diminution of the sedfative agents ; * patients with spontaneous beath in vac mode or patient ventilated in a vsai-pep mode; * pao2/fio2 ≥150; * absence d'inotropes ou de vasopresseurs à forte dose ou dose croissante (\<1mg/h); * sao2 \> 90% with fio2 ≤ 50%; * pep ≤ 8cmh2o; * corporal température between 36°c and 39°c; * glasgow score ≥ 8; * patient or family consent. exclusion criteria: * age \< 18 years ; * medically unstable; * poor vital pronostic at very short term; * cardiac arrest with a poor neurological prognostic; * neuromuscular disease ; * tracheostomy ; * current pregnancy ; * patients with guardianship or trusteeship.

Keywords: ventilated induced diaphragmatic dysfunction weaning inspiratory muscle training
dorzolamide+timolol multidose preservative-free vs dorzolamida+timolol bak preserved efficacy and safety

Conditions: Glaucoma, Open-Angle; Ocular Hypertension

Summary: the goal of this study is to evaluate the tolerability of the new formulation of dorzolamide+timolol preservative free developed in osd aptar pharma multidose system in comparison with dorzolamide +timolol bak preserved ophthalmic formulation.


Eligibility criteria:
inclusion criteria: * older than 18 years old * patients with poag and oh * pio \< 20 mmhg * under treatment with dorzolamide + timolol bak preserved at least 6 month after * osdi \> 13 \& one of these ocular signs (but \<6sec or schirmer test \< 5 mm/5min or corneal staining positive) * corneal thickness between 520-580 um. exclusion criteria: * patient with severe respiratory diseases (asthma, copd and other bronchospactic diseases). * patient with cardiovascular diseases (sinus bradycardia, av block, cardiac failure, cardiogenic shock). * severe renal impairment (crcl \<30 ml/min) * progressive diseases of the retina other than glaucoma * inflammation and/or infecctions active * ocular surface syndrome other than ocular surface disease * eyelid disorder * systemic adminsitration of betablockers or carbonic anhydrase inhibitors * patient that requires another antigluacomatous eye drop other than fixed combination of dorzolamide/timolol * patients who use regularly lubricant eye drops * patient who use regularly contact lenses * patient with autoinmune diseases * patients who underwent kerato-refractive laser procedures, cornea or corneal surface surgery, including, but not limited to, lasik and prk, within 6 months prior to the baseline visit. * patients who have undergone a laser procedure or intraocular surgery or extraocular in either eye within 6 months prior to the baseline visit. * patients with severe central visual field loss in either eye based onclinical judgment of the investigator. for the humphrey and octopus perimeters, the severe loss the visual field is defined as a sensitivity less than or equal to 10 db in at least two(2) of the four (4) visual field test points closest to the fixation point * patients with known hypersensitivity to any of the components of bothdrugs under study. * pregnant or lactating women. * women of childbearing age who are not using a contraceptive method.